Search

Displaying results 531 - 540 of 9407 in total
  1. Drug

    Lincomycin

    go.drugbank.com/drugs/DB01627
    ApprovedInvestigationalVet approved

    [A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964.[L33214] … Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska.

  2. Drug

    Metharbital

    go.drugbank.com/drugs/DB00463
    ApprovedWithdrawn

    Metharbital is a barbiturate anticonvulsant, similar to phenobarbital, marketed as Gemonil by Abbott Laboratories. It was patented in 1905 by Emil Fischer of Merck.

  3. Drug

    Homosalate

    go.drugbank.com/drugs/DB11064
    Approved

    Salicylates prevent direct skin exposure to the sun’s harmful rays by absorbing ultraviolet (UV) light. … Homosalate is an organic compound that belongs to salicylates. It is an ester formed from salicylic acid and 3,3,5-trimethylcyclohexanol, a derivative of cyclohexanol.

    Mixtures: Hope In A Jar SPF 25, b.tan Tropic Like Its Hot SPF 15
  4. Drug

    Amlodipine

    go.drugbank.com/drugs/DB00381
    ApprovedInvestigational

    Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. … Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321].

    Mixtures: RAMIPRIL E AMLODIPINA EG, RAMIPRIL E AMLODIPINA EGCategories: Angiotensin II receptor blockers (ARBs) and calcium channel blockers
  5. Drug

    Vosoritide

    go.drugbank.com/drugs/DB11928
    ApprovedInvestigational

    Endogenous CNP, first described in 1998, is primarily responsible for the stimulation of chondrocytes and long bone growth via activity at the NPR-B receptor, making it an attractive target in the treatment … [A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development

  6. Drug

    Valsartan

    go.drugbank.com/drugs/DB00177
    ApprovedInvestigational

    The angiotensin II receptor blocker (ARB) family of drugs unique in that it blocks all angiotensin II activity, regardless of where or how it was synthesized. … Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan].

    Mixtures: AMLODIPINA E VALSARTAN DOC, AMLODIPINA E VALSARTAN DOCCategories: Agents Acting on the Renin-Angiotensin System, Angiotensin 2 Receptor Blocker
  7. Drug

    Vitamin D

    go.drugbank.com/drugs/DB11094
    ApprovedInvestigationalNutraceuticalVet approved

    There are several different vitamin D supplements that are given to treat or to prevent osteomalacia and rickets, or to meet the daily criteria of vitamin D consumption. … Vitamin D3 and D2 require hydroxylation in order to become biologically active in the human body.

    Mixtures: TL-Fluorivite, Advanced B & T Formula
  8. Drug

    Tibolone

    go.drugbank.com/drugs/DB09070
    ApprovedInvestigational

    In June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S. … Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the development of osteoporosis [L1876].

    Categories: Sex Hormones and Modulators of the Genital System, Estrogen Receptor Modulators
  9. Drug

    Human thrombin

    go.drugbank.com/drugs/DB11571
    ApprovedInvestigational

    This transformation mimics the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and achieves hemostasis and sealing of open tissues. … Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.

    Mixtures: EVICEL® SELLANTE DE FIBRINA HUMANA
  10. Drug

    Indigotindisulfonic acid

    go.drugbank.com/drugs/DB11577
    ApprovedInvestigational

    [A32490,A32491,A32492] In 2022, the FDA approved the intravenous use of indigotindisulfonate sodium to aid in visualizing ureter integrity in cystoscopic assessments.[L42600] … [A251405] Indigotindisulfonic acid is used in clinical medicine to determine patency of the urinary collecting system, and to assist in specific surgical procedures such as cystourethroscopy.